377 related articles for article (PubMed ID: 17718858)
1. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
[TBL] [Abstract][Full Text] [Related]
2. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
[TBL] [Abstract][Full Text] [Related]
3. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
[TBL] [Abstract][Full Text] [Related]
4. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic mastectomy and genetic testing: an update.
Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
[TBL] [Abstract][Full Text] [Related]
6. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
7. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
[TBL] [Abstract][Full Text] [Related]
8. Decision-making process of women carrying a BRCA1 or BRCA2 mutation who have chosen prophylactic mastectomy.
McQuirter M; Castiglia LL; Loiselle CG; Wong N
Oncol Nurs Forum; 2010 May; 37(3):313-20. PubMed ID: 20439215
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling.
Wakefield CE; Meiser B; Homewood J; Taylor A; Gleeson M; Williams R; Tucker K;
Psychooncology; 2008 Aug; 17(8):844-54. PubMed ID: 18613319
[TBL] [Abstract][Full Text] [Related]
10. The prevention of hereditary breast cancer.
Rodriquez E; Domchek SM
Semin Oncol; 2007 Oct; 34(5):401-5. PubMed ID: 17920894
[TBL] [Abstract][Full Text] [Related]
11. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
12. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
Ardern-Jones A; Kenen R; Eeles R
Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973
[TBL] [Abstract][Full Text] [Related]
13. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
14. [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer].
Loman N
Lakartidningen; 2004 Jun; 101(25):2172-7. PubMed ID: 15281304
[TBL] [Abstract][Full Text] [Related]
15. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
[TBL] [Abstract][Full Text] [Related]
16. Can genetic testing guide treatment in breast cancer?
Tutt A; Ashworth A
Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
18. A multicenter study of supportive-expressive group therapy for women with BRCA1/BRCA2 mutations.
Esplen MJ; Hunter J; Leszcz M; Warner E; Narod S; Metcalfe K; Glendon G; Butler K; Liede A; Young MA; Kieffer S; DiProspero L; Irwin E; Wong J
Cancer; 2004 Nov; 101(10):2327-40. PubMed ID: 15478194
[TBL] [Abstract][Full Text] [Related]
19. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
van Dijk S; van Roosmalen MS; Otten W; Stalmeier PF
J Clin Oncol; 2008 May; 26(14):2358-63. PubMed ID: 18467728
[TBL] [Abstract][Full Text] [Related]
20. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]